Skip to main content
. 2013 Sep 3;8(9):e73310. doi: 10.1371/journal.pone.0073310

Figure 6. Therapeutic effects of anti-mouse CD115 mAb alone or combined with Paclitaxel in the PyMT mouse model.

Figure 6

At 16 weeks of age, transgenic PyMT mice were administered 50 mg/kg of mAb AFS98 or isotype control or PBS, IP, 3 times per week for 4 weeks, alone (A, B) or combined (C, D) with Paclitaxel at 5 mg/kg, IP, once a week for 3 weeks. A. Tumor volumes are represented as means ± SEM. * Mann-Whitney’s test p<0.05 for AFS98- compared to PBS-treated mice. At week 20, * p<0.05 for AFS98- and Rat IgG- vs PBS-treated mice. B. The percentage of surviving mice was significantly increased in the AFS98-treated group. * Log-rank test p<0.05 between AFS98- and Rat IgG-treated groups and ** p<0.005 between AFS98- and PBS-treated mice (n = 10). C. Tumor volumes are represented as means ± SEM. * Mann-Whitney’s test p<0.05 for the combination Paclitaxel+AFS98 compared with Paclitaxel+PBS, and p<0.01 compared with Paclitaxel+Rat IgG. **p<0.01 and ***p<0.001 for Paclitaxel+AFS98 compared with Paclitaxel+Rat IgG or PBS (n = 10). D. The percentage of surviving mice was significantly increased by AFS98 combined with Paclitaxel. ** Log-rank test p<0.01 for mice treated with Paclitaxel+AFS98 compared to Paclitaxel+Rat IgG or PBS.